Skip to Content

Generic Nurtec ODT Availability

Last updated on Sep 8, 2021.

Nurtec ODT is a brand name of rimegepant, approved by the FDA in the following formulation(s):

NURTEC ODT (rimegepant sulfate - tablet, orally disintegrating;oral)

  • Manufacturer: BIOHAVEN IRELAND
    Approval date: February 27, 2020
    Strength(s): EQ 75MG BASE [RLD]

Has a generic version of Nurtec ODT been approved?

No. There is currently no therapeutically equivalent version of Nurtec ODT available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nurtec ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 11,083,724

    Patent expiration dates:

    • March 25, 2039
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
      ✓ 
      Drug product
    • March 25, 2039
      ✓ 
      Patent use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
      ✓ 
      Drug product
  • CGRP receptor antagonists
    Patent 8,314,117
    Issued: November 20, 2012
    Inventor(s): Luo; Guanglin & Dubowchik; Gene M. & Macor; John E.
    Assignee(s): Bristol-Myers Squibb Company

    The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

    Patent expiration dates:

    • February 22, 2031
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 22, 2031
      ✓ 
      Patent use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
    Patent 8,759,372
    Issued: June 24, 2014
    Assignee(s): Bristol-Myers Squibb Company

    Disclosed is a hemisulfate salt of Compound (I): and crystalline forms of the hemisulfate salt. Also disclosed are methods of using the hemisulfate salt of Compound (I) as a CGRP receptor antagonist, and pharmaceutical compositions comprising the hemisulfate salt of Compound (I). The hemisulfate salt of Compound (I) is useful in treating, preventing, or ameliorating disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

    Patent expiration dates:

    • February 25, 2033
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • May 27, 2024 - FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
    • February 27, 2025 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.